Mollnes T E, Frøland S S, Harboe M
Complement. 1985;2(2-3):175-84. doi: 10.1159/000467858.
The terminal C5b-9 complex of human complement has recently been described and quantified in normal human plasma by an enzyme-linked immunosorbent assay (ELISA). We collected EDTA plasma samples from 20 patients clinically suspected to have complement activation. The terminal complement complex (TCC) and C3d split products were measured. The TCC was increased in 8 patients, and 6 of these also had increased C3d values, whereas 4 patients had increased C3d and normal TCC values. Two different double-antibody assays were used to detect terminal pathway activation: the combination of anti-C6 and anti-C9 detecting only the whole complex, and the combination of anti-C6 and anti-C5 detecting intermediate complexes as well. There was a close correlation between the observations in these two assays, suggesting that in general the whole cascade including C9 is involved when the terminal pathway of complement is activated in vivo. Quantification of TCC in plasma is an important supplement to already established methods for the evaluation of complement activation in vivo.
人补体终末C5b-9复合物最近已通过酶联免疫吸附测定（ELISA）在正常人血浆中得以描述和定量。我们从20名临床怀疑有补体激活的患者中采集了乙二胺四乙酸（EDTA）血浆样本。测定了终末补体复合物（TCC）和C3d裂解产物。8名患者的TCC升高，其中6名患者的C3d值也升高，而4名患者的C3d升高但TCC值正常。使用两种不同的双抗体测定法检测终末途径激活：抗C6和抗C9的组合仅检测完整复合物，抗C6和抗C5的组合还检测中间复合物。这两种测定法的观察结果之间存在密切相关性，表明在体内补体终末途径激活时，通常整个包括C9的级联反应都会参与。血浆中TCC的定量是对已确立的体内补体激活评估方法的重要补充。
